Neurogene Inc. — Director's Dealing 2014

Mar 14, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AQUINOX PHARMACEUTICALS, INC (AQXP)
CIK: 0001404644
Period of Report: 2014-03-12

Reporting Person: Main David (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-03-12	Common Special Voting Stock	D	9459	$11.00	Disposed	71530	Direct
2014-03-12	Common Special Voting Stock	C	71530	—	Disposed	0	Direct
2014-03-12	Common Stock	C	71530	—	Acquired	71530	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-03-12	Common Exchangeable Shares	$	D	9459	Disposed		Common Stock (9459)	Direct
2014-03-12	Common Exchangeable Shares	$	C	71530	Disposed		Common Stock (71530)	Direct

Footnotes

F1: Each share of the issuer's Common, Series A-1, Series A-2, Series B-1, Series B-2 and Series C Special Voting Stock was redeemed upon the closing of the issuer's initial public offering for $0.0000192 per share.

F2: The Common Exchangeable Shares of Aquinox Pharmaceuticals Inc., a corporation under the Canadian Business Corporations Act ("AQXP Canada"), were exchanged for Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and have no expiration date.